Nuvalent (NUVL) Price & Analysis

Compare

121 Followers

NUVL Stock Chart & Stats

Day’s Range― - ―

52-Week Range$55.54 - $113.51

Previous CloseN/A

Volume65.93K

Average Volume (3M)498.24K

Market Cap

$5.52B

Enterprise Value$4.48B

Total Cash (Recent Filing)$1.01B

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.28

Next Earnings

Nov 06, 2025

EPS Estimate

-1.36

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.39

Shares Outstanding66,669,586

10 Day Avg. Volume535,074

30 Day Avg. Volume498,238

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.81

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-12.36

Forecast

1Y Price Target

$115.25

Price Target Upside50.44% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

Bulls Say, Bears Say

Bulls Say

Drug DevelopmentNuvalent's highest profile asset is neladalkib (NVL-655), a potentially best in class ALK inhibitor.

FDA EngagementThe FDA is enthusiastic to evaluate the program given that it accepted the NDA under the Real-Time Oncology Review pilot program, which allows the agency to evaluate topline results in advance of the submission.

Financial StabilityNuvalent ended the quarter with cash and cash equivalents of approximately $1.0B, which is believed to be sufficient to fund operations for the foreseeable future.

Bears Say

Enrollment Timeline ConcernsSome investors are nervous about potentially lengthy enrollment/data timelines for the 1L trial given the number of patients required and the PFS associated with alectinib.

Financial PerformanceThe company reported no revenue for the quarter, in line with consensus, and a net loss of $1.39 per share, compared to the consensus estimated net loss of $1.22 per share.

Nuvalent News

Nuvalent reports Q2 EPS ($1.39), consensus ($1.15)

“With the initiation of our rolling NDA submission for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC and the...

7d ago

NUVL

Nuvalent doses first patient in Alkazar trial

Nuvalent (NUVL) announced that the first patient has been dosed in Alkazar, the company’s global Phase 3 randomized,...

24d ago

NUVL

Nuvalent Reports Q2 2025 Financials and Pipeline Progress

Nuvalent, Inc. Class A ( ($NUVL) ) has released its Q2 earnings. Here is a breakdown of the...

6d ago

NUVL

Nuvalent’s Promising Drug Pipeline and Strategic Trials Drive Buy Rating

TD Cowen analyst Marc Frahm has maintained their bullish stance on NUVL stock, giving a Buy rating today....

7d ago

NUVL

Nuvalent’s Promising Developments and Strong Financial Position Justify Buy Rating

Charles Zhu, an analyst from LifeSci Capital, maintained the Buy rating on Nuvalent. The associated price target remains...

7d ago

NUVL

Nuvalent’s Accelerated ALKAZAR Trial Progress and Strong Financials Justify Buy Rating

Nuvalent, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Charles Zhu from LifeSci...

24d ago

NUVL

Nuvalent Initiates Phase 3 ALKAZAR Clinical Trial

Nuvalent ( ($NUVL) ) has issued an update. On July 21, 2025, Nuvalent, Inc. announced the initiation of...

24d ago

NUVL

Nuvalent’s Promising Biotech Advancements: Buy Rating Backed by Strong Clinical Results

Goldman Sachs analyst Richard Law CFA has maintained their bullish stance on NUVL stock, giving a Buy rating...

1M ago

NUVL

Nuvalent assigned Buy rating, $105 price target at Goldman Sachs

Goldman Sachs assigned Nuvalent (NUVL) a Buy rating with a $105 price target having previously initiated coverage at...

1M ago

NUVL

Nuvalent price target raised to $112 from $105 at Baird

Baird raised the firm’s price target on Nuvalent (NUVL) to $112 from $105 and keeps an Outperform rating...

2M ago

NUVL

Nuvalent’s Zidesamtinib: A Promising Blockbuster in the ROS1 Inhibitor Landscape

Analyst Andrew Berens from Leerink Partners maintained a Buy rating on Nuvalent (NUVL – Research Report) and increased...

2M ago

NUVL

Nuvalent price target raised to $140 from $125 at Leerink

Leerink raised the firm’s price target on Nuvalent (NUVL) to $140 from $125 and keeps an Outperform rating...

2M ago

NUVL

Nuvalent price target raised to $130 from $110 at H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Nuvalent (NUVL) to $130 from $110 and...

2M ago

NUVL

Nuvalent’s Zidesamib: Promising Best-in-Class ROS1 TKI with Strong Efficacy and Safety Profile

In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on Nuvalent (NUVL –...

2M ago

NUVL

NUVL FAQ

What was Nuvalent’s price range in the past 12 months?

Nuvalent lowest stock price was $55.53 and its highest was $113.51 in the past 12 months.

What is Nuvalent’s market cap?

Nuvalent’s market cap is $5.52B.

When is Nuvalent’s upcoming earnings report date?

Nuvalent’s upcoming earnings report date is Nov 06, 2025 which is in 84 days.

How were Nuvalent’s earnings last quarter?

Nuvalent released its earnings results on Aug 07, 2025. The company reported -$1.39 earnings per share for the quarter, missing the consensus estimate of -$1.225 by -$0.165.

Is Nuvalent overvalued?

According to Wall Street analysts Nuvalent’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Nuvalent pay dividends?

Nuvalent does not currently pay dividends.

What is Nuvalent’s EPS estimate?

Nuvalent’s EPS estimate is -1.36.

How many shares outstanding does Nuvalent have?

Nuvalent has 66,669,586 shares outstanding.

What happened to Nuvalent’s price movement after its last earnings report?

Nuvalent reported an EPS of -$1.39 in its last earnings report, missing expectations of -$1.225. Following the earnings report the stock price went down -6.565%.

Which hedge fund is a major shareholder of Nuvalent?

Currently, no hedge funds are holding shares in NUVL

Nuvalent Stock Smart Score

Neutral

Fundamentals

Return on Equity

-43.55%

Trailing 12-Months

Asset Growth

54.10%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Nuvalent

Nuvalent, Inc. is an innovative biotechnology company focused on creating small molecule medicines for patients with cancer. The company specializes in developing precision-targeted therapies for clinically proven kinase targets in cancer treatment. Nuvalent's core products are designed to address the limitations of existing therapies, with a focus on resistance, selectivity, and brain penetration to provide significant improvements for patients.

Nuvalent (NUVL) Earnings & Revenues

Historic Earnings Reports

NUVL Stock 12 Month Forecast

Average Price Target

$115.25

▲(50.44% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"67":"$67","104":"$104","141":"$141","85.5":"$85.5","122.5":"$122.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":140,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$140.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":115.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$115.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$100.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[67,85.5,104,122.5,141],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,77.76,82.54769230769232,87.33538461538461,92.12307692307692,96.91076923076923,101.69846153846154,106.48615384615385,111.27384615384615,116.06153846153846,120.84923076923077,125.63692307692307,130.42461538461538,135.2123076923077,{"y":140,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,77.76,80.64384615384616,83.5276923076923,86.41153846153847,89.29538461538462,92.17923076923077,95.06307692307692,97.94692307692307,100.83076923076923,103.71461538461539,106.59846153846154,109.4823076923077,112.36615384615385,{"y":115.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,77.76,79.47076923076924,81.18153846153847,82.8923076923077,84.60307692307693,86.31384615384616,88.02461538461539,89.73538461538462,91.44615384615385,93.15692307692308,94.86769230769231,96.57846153846154,98.28923076923077,{"y":100,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":76.22,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.13,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.02,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.22,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.27,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.28,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.81,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.98,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.23,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.18,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.01,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.76,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >